Resource Summary Report  New Search Previous Search Results

URL: https://dx.doi.org/10.17504/protocols.io.bi35kgq6

Authors: Bei Wang, Daniel Asarnow, Wen-Hsin Lee, Ching-Wen Huang, Bryan Faust, Patricia Miang Lon Ng, Eve Zi Xian Ngoh, Markus Bohn, David Bulkley, Andrés Pizzorno, Hwee Ching Tan, Chia-Yin Lee, Rabiatul Adawiyah Minhat, Olivier Terrier, Mun Kuen Soh, Frannie Jiuyi Teo, Yvonne Yee Chin Yeap, Yuanyu Hu, Shirley Gek Kheng Seah, Sebastian Maurer-Stroh, Laurent Renia, Brendon John Hanson, Manuel Rosa-Calatrava, Aashish Manglik, Yifan Cheng, Charles S. Craik, Cheng-I Wang

Group: Coronavirus Method Development Community

Summary: In vitro antibody selection against pathogens from naïve combinatorial libraries can yield various classes of antigen-specific binders that are distinct from those evolved from natural infection. Also, rapid neutralizing antibody discovery can be made possible by a strategy that selects for those interfering with pathogen and host interaction. Here we report the discovery of antibodies that neutralize SARS-CoV-2, the virus responsible for the COVID-19 pandemic, from a highly diverse naïve human Fab library. Lead antibody 5A6 blocks the receptor binding domain (RBD) of the viral spike from binding to the host receptor angiotensin converting enzyme 2 (ACE2), neutralizes SARS-CoV-2 infection of Vero E6 cells, and reduces viral replication in reconstituted human nasal and bronchial epithelium models. 5A6 has a high occupancy on the viral surface and exerts its neutralization activity via a bivalent binding mode to the tip of two neighbouring RBDs at the ACE2 interaction interface, one in the “up” and the other in the “down” position, explaining its superior neutralization capacity. Furthermore, 5A6 is insensitive to several spike mutations identified in clinical isolates, including the D614G mutant that has become dominant worldwide. Our results suggest that 5A6 could be an effective prophylactic and therapeutic treatment of COVID-19.

Affiliations: Singapore Immunology Network, A*STAR, Singapore, Department of Biochemistry and Biophysics, University of California San Francisco (UCSF) School of Medicine, San Francisco, USA; QBI COVID-19 Research Group (QCRG), San Francisco, USA, Singapore Immunology Network, A*STAR, Singapore, Singapore Immunology Network, A*STAR, Singapore, Department of Biochemistry and Biophysics, University of California San Francisco (UCSF) School of Medicine, San Francisco, USA; QBI COVID-19 Research Group (QCRG), San Francisco, USA, Singapore Immunology Network, A*STAR, Singapore, Singapore Immunology Network, A*STAR, Singapore, QBI COVID-19 Research Group (QCRG), San Francisco, USA; Department of Pharmaceutical Chemistry, University of California San Francisco (UCSF), San Francisco, USA, Department of Biochemistry and Biophysics, University of California San Francisco (UCSF) School of Medicine, San Francisco, USA; QBI COVID-19 Research Group (QCRG), San Francisco, USA, Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, Lyon, France, Singapore Immunology Network, A*STAR, Singapore, Singapore Immunology Network, A*STAR, Singapore, Singapore Immunology Network, A*STAR, Singapore, Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, Lyon, France, Singapore Immunology Network, A*STAR, Singapore, Singapore Immunology Network, A*STAR, Singapore, Singapore Immunology Network, A*STAR, Singapore, Singapore Immunology Network, A*STAR, Singapore, Biological Defence Program, DSO National Laboratories, Singapore, Bioinformatics Institute, A*STAR, Singapore, Singapore Immunology Network, A*STAR, Singapore; School of Biological Sciences, Nanyang Technological University, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Biological Defence Program, DSO National Laboratories, Singapore, Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, Lyon, France; VirNext, Faculté de Médecine RTH Laennec, Université de Lyon, Lyon, France, QBI COVID-19 Research Group (QCRG), San Francisco, USA; Department of Pharmaceutical Chemistry, University of California San Francisco (UCSF), San Francisco, USA; Department of Anesthesia and Perioperative Care, University of California San Francisco (UCSF), San Francisco, USA, Department of Biochemistry and Biophysics, University of California San Francisco (UCSF) School of Medicine, San Francisco, USA; QBI COVID-19 Research Group (QCRG), San Francisco, USA; Howard Hughes Medical Institute, University of California San Francisco (UCSF), San Francisco, USA, QBI COVID-19 Research Group (QCRG), San Francisco, USA; Department of Pharmaceutical Chemistry, University of California San Francisco (UCSF), San Francisco, USA, Singapore Immunology Network, A*STAR, Singapore

External URL: https://www.biorxiv.org/content/10.1101/2020.07.14.203414v1?rss=1

Version: 1

Publication Date: 2020

Expand All Collapse